Collective Family Office’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Collective Family Office’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-119,420	Closed	-$106K	–	185
2022 Q4	$106K	Buy	119,420 +13,500	+13%	+$17.9K	0.05%	169
2022 Q3	$166K	Buy	105,920 +7,175	+7%	+$16.3K	0.08%	164
2022 Q2	$198K	Buy	98,745 +11,735	+13%	+$20.3K	0.09%	181
2022 Q1	$203K	Buy	87,010 +19,200	+28%	+$59.9K	0.08%	187
2021 Q4	$315K	Buy	67,810 +23,607	+53%	+$147K	0.12%	143
2021 Q3	$337K	Buy	44,203 +15,443	+54%	+$131K	0.14%	131
2021 Q2	$279K	Buy	28,760 +6,075	+27%	+$48.4K	0.12%	144
2021 Q1	$188K	Buy	22,685 +725	+3%	+$7.66K	0.09%	164
2020 Q4	$150K	Buy	+21,960	New	+$176K	0.08%	150

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Collective Family Office's SRNE Position: Q1 2023 in Review

Collective Family Office sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 119,420 shares — an estimated $106K sold.

Collective Family Office first reported a position in SRNE in Q4 2020 and held it in 9 quarters. The position peaked at $337K in Q3 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Collective Family Office reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Collective Family Office sold 119,420 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $106K.
Collective Family Office first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 9 quarters.
Collective Family Office's Sorrento Therapeutics, Inc. position peaked at $337K in Q3 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Collective Family Office's 13F filing for Q1 2023, filed 12 Apr 2023.